Last Updated : November 20, 2024
Details
Generic Name:
blinatumomab
Project Status:
Active
Therapeutic Area:
B-cell precursor acute lymphoblastic leukemia
Manufacturer:
Amgen Canada Inc.
Call for patient/clinician input open:
Brand Name:
Blincyto
Project Line:
Reimbursement Review
Project Number:
PC0365-000
Call for patient/clinician input closed:
Tumour Type:
Leukemia
NOC Status at Filing:
Pre NOC
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
For
the treatment of patients with Philadelphia chromosome-negative CD19 positive B-cell precursor
acute lymphoblastic leukemia in the consolidation phase of multiphase chemotherapy.
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For
the treatment of patients with Philadelphia chromosome-negative CD19 positive B-cell precursor
acute lymphoblastic leukemia in the consolidation phase of multiphase chemotherapy.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of Canada's Drug Agency. Reimbursement criteria from Canada's Drug Agency will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 06-Sep-24 |
|---|---|
| Call for patient/clinician input closed | 25-Nov-24 |
| Submission received | 18-Oct-24 |
| Submission accepted | 01-Nov-24 |
| Review initiated | 04-Nov-24 |
| Draft CADTH review report(s) provided to sponsor for comment | 27-Jan-25 |
| Deadline for sponsors comments | 05-Feb-25 |
| CADTH review report(s) and responses to comments provided to sponsor | 28-Feb-25 |
| Expert committee meeting (initial) | 12-Mar-25 |
| Draft recommendation issued to sponsor | March 25, 2025 To March 27, 2025 |
| Draft recommendation posted for stakeholder feedback | 03-Apr-25 |
| End of feedback period | 17-Apr-25 |
Last Updated : November 20, 2024